SuperworthZenas BioPharma price to book ratio ZBIO
Market value divided by the book value of the company's net assets, since 2024.
- Today, Oct 23, 2026
- 7.1×
- Peer median
- 2.8×
Zenas BioPharma's price to book ratio is 7.1× as of Oct 23, 2026.
The median for 10 large drugmakers of a similar size is 2.8×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 7.1× | 3.3× | 9.4× |
| 2025 | 11.6× | 0.8× | 11.6× |
| 2024 | 1.1× | 1.0× | 2.0× |
Against its peers
Companies in Drug Manufacturers - General nearest Zenas BioPharma's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| ZBIOZenas BioPharma | 7.1× |
| ANIPANI Pharmaceuticals | 2.8× |
| PAHCPhibro Animal Health | 4.1× |
| HRMYHarmony Biosciences | 2.1× |
| ANABAnaptysbio | 138× |
| PCRXPacira BioSciences | 2.2× |
| PBHPrestige Consumer Healthcare | 1.2× |
| OMEROmeros | n/m |
| NRIXNurix Therapeutics | 2.9× |
| AMPHAmphastar Pharmaceuticals | 1.4× |
| OGNOrganon | 3.6× |
| Peer median | 2.8× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Zenas BioPharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.